百济神州将在2025年欧洲血液学协会年会展示血液学产品组合新数据

百济神州
May 15

31篇摘要的数据展现出百济神州坚定致力于改变B细胞恶性肿瘤治疗现状四场口头报告重点介绍在研BTK蛋白降解剂BGB-16673和BCL2抑制剂索托克拉用于治疗多种B细胞恶性肿瘤的最新数据美国加州圣卡洛斯——百济神州有限公司(纳斯达克代码:ONC;香港联交所代码:06160;上交所代码:688235)是一家全球肿瘤治疗创新公司,今日宣布将于6月12日至15日在意大利米兰举行的欧洲血液学协会(EHA)年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10